Preventing colon and rectal cancer spread after surgery
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests medicines given around the time of colon or rectal cancer surgery to help lower the chance the cancer will later spread to other parts of the body. If you are planned for curative (potentially curable) surgery and have no signs of spread yet, the trial may help prevent future metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled for curative surgery to remove your colon or rectal cancer
- Your cancer is in one area (single colon or rectal tumor) confirmed by colonoscopy and biopsy
- Pre-surgery scans show no spread (no metastases) and you can get the needed scans
- Your general health is good enough (ASA 1–3 or ECOG 0–1)
- You can sign consent and follow study visits and instructions
- You are age 20 to 80
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two common medications before and after surgery can slow the growth of ovarian cancer. The medications may help reduce stress signals that could make cancer spread faster during surgery.
This trial tests if taking a medicine called propranolol around the time of surgery can improve outcomes for people with stomach or colon cancer that can be removed with an operation. Propranolol is a type of drug that blocks certain stress signals in the body and may help with recovery.
This trial tests whether adding a blood-pressure medicine (propranolol) to a combination of two immunotherapy drugs plus chemotherapy is safe and works better for locally advanced colon cancer that has not spread. It's for tumors that are pMMR/MSS, which are less likely to respond to immunotherapy alone, so the propranolol may help the immune system fight the cancer.
This trial tests treatments given before surgery for colorectal cancer that has not spread. The goal is to shrink the tumor and improve surgical outcomes. It may be an option for patients with stage II or III colorectal cancer who have not had prior treatment.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
This study tests a new combination treatment for stomach cancer that has not spread. You will receive propranolol (a beta-blocker), chemotherapy (SOX), and immunotherapy (toripalimab) before surgery to see if it helps shrink the tumor and improve outcomes.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.